View Author
patient hbsag hepatitis hepatitis b treatment therapy study level hbeag baseline response decline virological hbeag-positive virological response hepatology hbeag-positive patients virus hbv dna hbsag decline hbeag-negative patients cirrhosis serum disease hbeag-negative hbeag seroconversion resistance entecavir probability follow-up liver seroconversion antigen tenofovir peg-ifn hbsag loss analysis month tenofovir disoproxil fumarate hepatitis b virus effect hbv dna levels genotype disease progression hbsag seroclearance gastroenterology result surface hepatitis b patients population hbsag levels event peginterferon week 48 lamivudine progression figure clearance decompensated kinetic nucleo na-na mutant ënten hbsag kinetics seroclearance ef ficacy analogue hbv genotype infection monotherapy history hepatol rotterdam group hbeag loss combination european etv monotherapy factor
9 Most Recent Publications
|
Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis
(Article)
Zoutendijk, R. Reijnders, J.G.P. Berg, T. Hansen, B.E. Sonneveld, M.J. Wedemeyer, H. Janssen, H.L.A. Zoulim, F. Brown, A. Mutimer, D.J. Deterding, K. Hofmann, W.P. Petersen, J. Fasano, M. Buti, M. |
2013-05-01
|
|
Precore and core promoter mutants are associated with higher HBeAg seroconversion but low disease remission rates in HBV patients treated with nucleos(t)ide analogues
(Article)
Zoutendijk, R. Sonneveld, M.J. Reijnders, J.G.P. Vuuren, A.J. van Biesta, P.J. Hansen, B.E. Boonstra, A. Janssen, H.L.A. |
2013-05-01
|
|
Long-term clinical outcome of antiviral therapy for chronic hepatitis B
(Doctoral Thesis)
Zoutendijk, R. |
2012-12-21
|
|
Hepatitis B surface antigen declines and clearance during long-term tenofovir therapy in patients coinfected with HBV and HIV
(Article)
Zoutendijk, R. Zaaijer, H.L. Janssen, H.L.A. Vries-Sluijs, T.E.M.S. de Reijnders, J.G.P. Mulder, J. Kroon, F.P. Eijk, A.C. van der Sonneveld, M.J. Man, R.A. de Ende, M.E. van der |
2012-09-15
|
|
Efficacy and tolerance of a combination of tenofovir disoproxil fumarate plus emtricitabine in patients with chronic hepatitis B: A European multicenter study
(Article)
Si-Ahmed, S.N. Pradat, P. Wedemeyer, H. Janssen, H.L.A. Zoulim, F. Zoutendijk, R. Buti, M. Mallet, V. Cruiziat, C. Deterding, K. Dumortier, J. Bailly, F. Esteban, R. |
2011-10-01
|
|
Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss
(Article)
Zoutendijk, R. Hansen, B.E. Vuuren, A.J. van Boucher, C.A.B. Janssen, H.L.A. |
2011-08-01
|
|
Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response
(Article)
Zoutendijk, R. Reijnders, J.G.P. Bömmel, F. van Pradat, P. Oo, Y. Luetgehetmann, M. Berg, T. Hansen, B.E. Wedemeyer, H. Janssen, H.L.A. Brown, A. Zoulim, F. Mutimer, D. Deterding, K. Petersen, J. Hofmann, W.P. Buti, M. Santantonio, T. |
2011-08-01
|
|
Hepatitis B surface antigen monitoring and management of chronic hepatitis B
(Article)
Sonneveld, M.J. Zoutendijk, R. Janssen, H.L.A. |
2011-07-01
|
|
Fluid, electrolyte and acid-base disorders associated with antibiotic therapy
(Article)
Zietse, R. Zoutendijk, R. Hoorn, E.J. |
2009-04-01
|
